Zydus Cadila gets US health regulator nod for multiple sclerosis treatment drug

Zydus Cadila has received final approval from the United States Food and Drug Administration (USFDA) to market Dimethyl Fumarate delayed release capsules, (Tecfidera) in the strengths of 120 mg and 240 mg, Zydus Cadila, part of Cadila Healthcare group, said in a regulatory filing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2SaxzRH
via IFTTT